The Pathology of Amyloidosis in Classification: A Review

被引:181
作者
Picken, Maria M. [1 ]
机构
[1] Loyola Univ Med Ctr, Dept Pathol, 2160 S First Ave, Maywood, IL 60153 USA
关键词
Amyloidosis; Hereditary; Organ system; Pathology; LEUKOCYTE CHEMOTACTIC FACTOR-2; TRANSTHYRETIN CARDIAC AMYLOIDOSIS; ALPHA-CHAIN AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; RENAL AMYLOIDOSIS; MASS-SPECTROMETRY; CLINICOPATHOLOGICAL CORRELATIONS; PARAFFIN IMMUNOFLUORESCENCE; HEREDITARY FIBRINOGEN; AL AMYLOIDOSIS;
D O I
10.1159/000506696
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:The amyloidoses are a rare and heterogeneous group of disorders that are characterized by the deposition of abnormally folded proteins in tissues ultimately leading to organ damage. The deposits are mainly extracellular and are recognizable by their affinity for Congo red and their yellow-green birefringence under polarized light. Current classification of amyloid in medical practice is based on the amyloid protein type. To date, 36 proteins have been identified as being amyloidogenic in humans.Summary:in clinical practice, it is critical to distinguish between treatable versus non-treatable amyloidoses. Moreover, amyloidoses with a genetic component must be distinguished from the sporadic types and systemic amyloidoses must be distinguished from the localized forms. Among the systemic amyloidoses, AL continues to be the most common amyloid diagnosis in the developed world; other clinically significant types include AA, ALECT2, and ATTR. The latter is emerging as an underdiagnosed type in both the hereditary and wild-type setting. Other hereditary amyloidoses include AFib, several amyloidoses derived from apolipoproteins, AGel, ALys, etc. In a dialysis setting, systemic amyloid derived from beta(2) microglobulin (A beta 2M) should be considered, although a very rare hereditary variant has also been reported; several amyloidoses may be typically associated with aging and several iatrogenic types have also emerged. Determination of the amyloid protein type is imperative before specific therapy can be implemented and the current methods are briefly summarized. A brief overview of the target organ involvement by amyloid type is also included.Key Messages:(1) Early diagnosis of amyloidosis continues to pose a significant challenge and requires the participation of many clinical and laboratory specialties. (2) Determination of the protein type is imperative before specific therapy can be implemented. (3) While mass spectrometry has emerged as the preferred method of amyloid typing, careful application of immune methods is still clinically useful but caution and experience, as well as awareness of the limitations of each method, are necessary in their interpretation. (4) While the spectrum of amyloidoses continues to expand, it is critical to distinguish between those that are currently treatable versus those that are untreatable and avoid causing harm by inappropriate treatment.
引用
收藏
页码:322 / 334
页数:13
相关论文
共 85 条
[1]   Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits [J].
Abildgaard, Niels ;
Rojek, Aleksandra M. ;
Moller, Hanne E. H. ;
Palstrom, Nicolai Bjodstrup ;
Nyvold, Charlotte Guldborg ;
Rasmussen, Lars Melholt ;
Hansen, Charlotte Toftmann ;
Beck, Hans Christian ;
Marcussen, Niels .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2020, 27 (01) :59-66
[2]   Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy [J].
Adams, David ;
Ando, Yukio ;
Beirao, Joao Melo ;
Coelho, Teresa ;
Gertz, Morie A. ;
Gillmore, Julian D. ;
Hawkins, Philip N. ;
Lousada, Isabelle ;
Suhr, Ole B. ;
Merlini, Giampaolo .
JOURNAL OF NEUROLOGY, 2021, 268 (06) :2109-2122
[3]   Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management [J].
Baumgart, Julius-Valentin ;
Stuhlmann-Laeisz, Christiane ;
Hegenbart, Ute ;
Nattenmueller, Johanna ;
Schoenland, Stefan ;
Krueger, Sandra ;
Behrens, Hans-Michael ;
Roecken, Christoph .
VIRCHOWS ARCHIV, 2018, 473 (05) :627-637
[4]  
Benson MD., 2015, CURRENT CLIN PATHOLO, P65, DOI [10.1007/978-3-319-19294-9_5, DOI 10.1007/978-3-319-19294-9_5]
[5]   Leukocyte chemotactic factor 2: A novel renal amyloid protein [J].
Benson, Merrill D. ;
James, Sam ;
Scott, Katherine ;
Liepnieks, Juris J. ;
Kluve-Beckerman, Barbara .
KIDNEY INTERNATIONAL, 2008, 74 (02) :218-222
[6]   Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee [J].
Benson, Merrill D. ;
Buxbaum, Joel N. ;
Eisenberg, David S. ;
Merlini, Giampaolo ;
Saraiva, Maria J. M. ;
Sekijima, Yoshiki ;
Sipe, Jean D. ;
Westermark, Per .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2018, 25 (04) :215-219
[7]   Obesity is a significant susceptibility factor for idiopathic AA amyloidosis [J].
Blank, Norbert ;
Hegenbart, Ute ;
Dietrich, Sascha ;
Brune, Maik ;
Beimler, Joerg ;
Roecken, Christoph ;
Mueller-Tidow, Carsten ;
Lorenz, Hanns-Martin ;
Schoenland, Stefan O. .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2018, 25 (01) :37-45
[8]   Transthyretin Cardiac Amyloidosis in Older Americans [J].
Brunjes, Danielle L. ;
Castano, Adam ;
Clemons, Autumn ;
Rubin, Jonah ;
Maurer, Mathew S. .
JOURNAL OF CARDIAC FAILURE, 2016, 22 (12) :996-1003
[9]   Globular Hepatic Amyloid Is Highly Sensitive and Specific for LECT2 Amyloidosis [J].
Chandan, Vishal S. ;
Shah, Sejal S. ;
Lam-Himlin, Dora M. ;
De Petris, Giovanni ;
Mereuta, Oana M. ;
Dogan, Ahmet ;
Torbenson, Michael S. ;
Wu, Tsung-Teh .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (04) :558-564
[10]   Fibrinogen alpha amyloidosis: insights from proteomics [J].
Chapman, Jessica ;
Dogan, Ahmet .
EXPERT REVIEW OF PROTEOMICS, 2019, 16 (09) :783-793